Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Information (Tables)

v3.22.2
Balance Sheet Information (Tables)
6 Months Ended
Jun. 30, 2022
Balance Sheet Information  
Summary of cash and cash equivalents and restricted cash

A summary of cash and cash equivalents and restricted cash is as follows:

June 30, 2022

    

(unaudited)

    

December 31, 2021

Cash and Cash Equivalents

$

2,427,902

$

7,854,690

Restricted Cash, Non-current

 

49,307

 

45,000

Total Cash, Cash Equivalents and Restricted Cash

$

2,477,209

$

7,899,690

Schedule of accrued expenses

June 30, 2022

   

(unaudited)

   

December 31, 2021

Executive Severance

$

896,524

$

200,605

Payroll and Benefits

362,736

737,365

Professional Fees

 

313,853

 

194,425

Clinical Trials

 

58,287

 

168,785

Other

28,961

Total Accrued Expenses

$

1,631,400

$

1,330,141